Stafford and Elasy Matthews DR, Charbonnel BH, Hanefeld M, et al. 2005. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev, 21:167–74. Mazzone T, Meyer PM, Feinstein SB, et al. 2006. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. JAMA, 296:2572–81. Meigs JB, Larson MG, D’Agostino RB, et al. 2002. Coronary artery cal- ciﬁcation in type 2 diabetes and insulin resistance: the framingham offspring study. Diabetes Care, 25:1313–9. Meigs JB, Mittleman MA, Nathan DM, et al. 2000. Hyperinsulinemia, hyperglycemia, and impaired hemostasis: the Framingham Offspring Study. JAMA, 283:221–8. Miyazaki Y, Mahankali A, Matsuda M, et al. 2002. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab, 87:2784–91. Moller DE. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metab, 11:212–7. Natali A, Baldeweg S, Toschi E, et al. 2004. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Diabetes Care, 27:1349–57. Nolan JJ, Ludvik B, Beerdsen P, et al. 1994. Improvement in glucose toler- ance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med, 331:1188–93. Ovalle F, Bell DS. 2004. Effect of rosiglitazone versus insulin on the pan- creatic beta-cell function of subjects with type 2 diabetes. Diabetes Care, 27:2585–9. Perez A, Khan M, Johnson T, et al. 2004. Pioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetes. Diab Vasc Dis Res, 1:44–50. Perriello G, Misericordia P, Volpi E, et al. 1994. Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes, 43:920–8. Pischon T, Girman CJ, Hotamisligil GS, et al. 2004. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA, 291:1730–7. Polonsky KS, Sturis J, Bell GI. 1996. Seminars in Medicine of the Beth Israel Hospital, Boston. Non-insulin-dependent diabetes mellitus – a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med, 334:777–83. Roe MW, Worley JF 3rd, Tokuyama Y, et al. 1996. NIDDM is associated with loss of pancreatic beta-cell L-type Ca2+ channel activity. Am J Physiol, 270:E133–40. Rosenstock J, Sugimoto D, Strange P, et al. 2006. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naive patients. Diabetes Care, 29:554–9. Rossetti L, DeFronzo RA, Gherzi R, et al. 1990. Effect of metformin treat- ment on insulin action in diabetic rats: in vivo and in vitro correlations. Metabolism, 39:425–35. Saad MF, Knowler WC, Pettitt DJ, et al. 1988. The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med, 319:1500–6. Saad MF, Knowler WC, Pettitt DJ, et al. 1989. Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. Lancet, 1:1356–9. Samaha FF, Szapary PO, Iqbal N, et al. 2006. Effects of rosiglitazone on lipids, adipokines, and inﬂammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol, 26:624–30. TakedaPharmaceuticals Actosplus Met. Prescribing information [online]. Accessed 25 July 2007. URL: http://www.actos.com/actos/prescrib- inginfo.aspx UKPDS. 1998. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet, 352:854–65. Umpierrez G, Issa M, Vlajnic A. 2006. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial. Curr Med Res Opin, 22:751–9. Unger RH. 2005. Longevity, lipotoxicity and leptin: the adipocyte defense against feasting and famine. Biochimie, 87:57–64. Weissman P, Goldstein BJ, Rosenstock J, et al. 2005. Effects of rosigli- tazone added to submaximal doses of metformin compared with dose escalation of metformin in type 2 diabetes: the EMPIRE Study. Curr Med Res Opin, 21:2029–35. Wilson PW, D’Agostino RB, Parise H, et al. 2005. Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus. Circulation, 112:3066–72. Wilson PW, D’Agostino RB, Sullivan L, et al. 2002. Overweight and obesity as determinants of cardiovascular risk: the Framingham experience. Arch Intern Med, 162:1867–72. Xiang AH, Peters RK, Kjos SL, et al. 2006. Effect of pioglitazone on pan- creatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes. Diabetes, 55:517–22. Ye JM, Dzamko N, Cleasby ME, et al. 2004. Direct demonstration of lipid sequestration as a mechanism by which rosiglitazone prevents fatty- acid-induced insulin resistance in the rat: comparison with metformin. Diabetologia, 47:1306–13. Ye JM, Frangioudakis G, Iglesias MA, et al. 2002. Prior thiazolidinedione treatment preserves insulin sensitivity in normal rats during acute fatty acid elevation: role of the liver. Endocrinology, 143:4527–35. Yki-Jarvinen H. 2004. Thiazolidinediones. N Engl J Med, 351:1106–18. 510 Vascular Health and Risk Management 2007:3(4)